Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety and PK Study of DZD8586 in Healthy Adults
NCT05176873Phase 1Completed
- Sponsor
- Dizal Pharmaceutical Co., Ltd.
- Start
- Dec 2021
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in non-Hodgkin lymphoma (NHL) comparing DZD8586 with Placebo (2 arms). Primary endpoint: Number and percentage of participants with adverse event, serious adverse event. Started Dec 2021; status: completed.
02
Drugs
birelentinib
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT05176873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05176873.